Category: 42518-42-3

On July 12, 1973, Narr, Berthold; Woitun, Eberhard published a patent.HPLC of Formula: 42518-42-3 The title of the patent was Thrombocyte aggregation-inhibiting thieno[2,3-d]pyrimidines. And the patent contained the following:

Twenty-seven thienopyrimidines [I; R, R1 = H or Me; X = NH(CH2)2NH2 or NH(CH2)5NH2; X, Y = 1-pyrrolidinyl, 1-piperazinyl, 4-methyl-1-piperazinyl, piperidino, morpholino, 2-methylmorpholino, or thiomorpholino and its S-oxide or S,S-dioxide] were prepared by reaction of I (X, Y = Cl, SO2Me, SO2Et, or X or Y one of above substituents) with XH and(or) YH. I have a thrombocyte aggregation-inhibiting effect. Thus, KOCN in H2O was added to Et 2-amino-4,5-dimethyl-3-thiophenecarboxylate at 33.5.degree. and the mixture stirred 10 hr at room temperature to give 70% 5,6-dimethyl-2,4-dihydroxythieno[2,3-d]pyrimidine (II). II in POCl3 was heated 6 hr at 180° in a bomb tube to give 81% I (R = R1 = Me, X = Y = Cl) (III). III and morpholine were refluxed 2 hr to give 72% I (R = R1 = Me, X = Y = morpholino). The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).HPLC of Formula: 42518-42-3

The Article related to thienopyrimidine thrombocyte aggregation inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 5, 1980, Ishikawa, Fumiyoshi; Ashida, Shinichiro published a patent.Category: pyrimidines The title of the patent was 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones and pharmaceutical compositions containing them. And the patent contained the following:

The title compounds I (R, R1 = H, alkyl, Ph, Cl; RR1 = C3-5 alkylene; R2 = H, alkyl) and some isomers in the thiophene ring were prepared Thus 2,4-dichloro-5,6-dimethylthieno[2,3-d]pyrimidine was hydrogenated and cyclized with BrCH2CO2Et to give I (R = R1 = Me, R2 = H, II). II had blood platelet aggregation-inhibiting activity of 84% at 50 mg/kg orally in rats and caused 5 ± 3% decrease in blood pressure at the same dose. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Category: pyrimidines

The Article related to imidazothienopyrimidinone, platelet aggregation inhibitor imidazothienopyrimidinone, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 1986, Boehm, R.; Pech, R.; Haubold, Gudrun; Hannig, E. published an article.Computed Properties of 42518-42-3 The title of the article was Thieno compounds. Part 5. Base substituted thieno[2,3-d]pyrimidines. And the article contained the following:

Thienopyrimidines I and II [R = Cl, substituted NH2; R1 = substituted NH2] were prepared by the amination of I or II (R, R1 = Cl). Stepwise amination of I or II (R, R1 = Cl) gave mixed diaminothienopyrimidines. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Computed Properties of 42518-42-3

The Article related to chlorothienopyrimidine amination, thienopyrimidinamine, aminothienopyrimidine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 29, 2007, Han, Cheol Kyu; Yoon, Jeonghyeok; Kim, Nam-Doo; Kim, Jin-Ah published a patent.SDS of cas: 42518-42-3 The title of the patent was Preparation of 5,6-dimethylthieno[2,3-d]pyrimidine derivatives as antiviral agents. And the patent contained the following:

Title compounds represented by the formula I [wherein R1 = 4-morpholinophenyl or 6-morpholinopyridin-3-yl; R2 = 2-, 3- or 4-pyridinyl; and pharmaceutically acceptable salts thereof] were prepared as antiviral agents. For example, reaction of 2,4-dichloro-5,6-dimethylthieno[2,3-d]pyrimidine with 4-(morpholino)aniline (quant.), and followed by reaction with piperazine (15%) and picolinoyl chloride hydrochloride (30%), gave I (R1 = 4-morpholinophenyl, R2 = 2-pyridinyl). The title compounds I showed HCV replicon inhibitory activity with EC50 values of 0.45 – 0.71 μM, and low cytotoxicity. Thus, I and their pharmaceutical compositions are useful for the treatment of hepatitis C. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).SDS of cas: 42518-42-3

The Article related to dimethylthienopyrimidine morpholinophenyl preparation hcv inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 17, 2000, Pamukcu, Rifat; Piazza, Gary A. published a patent.Recommanded Product: 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine The title of the patent was Preparation of thienopyrimidines for inhibiting neoplastic cell growth. And the patent contained the following:

Title compounds [I; R = (un)substituted phenyl(alkyl); R1,R2 = H, halo, alkyl, alkoxy, etc.; R1R2 = alkylene; R3 = (un)substituted cycloalkyl, -heterocyclyl, -(hetero)aryl, etc.] were prepared for inhibiting neoplastic cell growth (no data). Thus, 2,4-dichloro-6-methylthieno[2,3-d]pyrimidine was aminated by 3,4-methylenedioxybenzylamine to give I (R = 3,4-methylenedioxybenzyl, R1 = Me, R2 = H)(II; R3 = Cl) which was condensed with Et piperidine-4-carboxylate to give II (R3 = 4-ethoxycarbonylpiperidino). The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Recommanded Product: 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

The Article related to thienopyrimidine preparation neoplastic cell growth inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 4, 1985, Boehm, Ralf; Haubold, Gudrun; Pech, Reinhard; Laban, Gunter published a patent.Quality Control of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine The title of the patent was Arylamino-substituted thieno[2,3-d]pyrimidines. And the patent contained the following:

Blood platelet aggregation inhibiting (no data) title compounds [I; R1 = R2 = Me; R1R2 = (CH2)4; R3 = R5 = H; R4 = R6 = aryl; R5R6N = saturated, monocyclic heterocydyl] were prepared by aminolysis of 2,4-dichlorothieno[2,3-d]pyrimidines. Thus, 2,4-dichloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine was refluxed 6 h with 2-MeC6H4NH2 in PrOH to give 2-o-toluidino derivative II (R7 = Cl). This was refluxed with morpholine to give II (R7 = morpholino). The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Quality Control of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

The Article related to blood platelet aggregation inhibition thienopyrimidinediamine, thienopyrimidinediamine, benzothienopyrimidinediamine, aminolysis chlorothienopyrimidine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 4, 2021, Xu, Qing; Li, Zhe; Nilar, Shahul published a patent.Safety of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine The title of the patent was Preparation of thienopyrimidines as ferroportin inhibitors. And the patent contained the following:

The invention is related to the preparation of compounds I [R1, R2 = independently H, alkyl, halo, 5- or 6-membered heteroaryl; Z = N, CH; R6 = independently at each occurrence halogen, hydroxy, alkoxy, cycloalkyl, etc.; n = 0-3; Y1 = absent or present; Y1, if present, and Y2, and Y3 = independently selected N, CH, and C (when R6 is attached thereto); R3 = H, alkyl, hydroxyalkyl; R4 = CR4cR4dCONR4aR4b, CH2CH2NR4eR4f, CH2CH2OR4g; R4a = H, alkyl; R4b = H, alkyl, cycloalkyl, 5- to 7-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl; or NR4aR4b = 5- to 7-membered heterocyclyl; R4c i= H, alkyl, cycloalkyl, hydroxyalkyl; R4d = H, alkyl; or CR4cR4d = cycloalkyl or 5- to 7-membered heterocyclyl; R4e = H, alkyl, C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, and C6-C10 aryl; R4f = H, alkyl; NR4eR4f = 5- to 7-membered heterocyclyl; R4g = H, alkyl, cycloalkyl, 5- to 7-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl; wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl of R4b, R4c, R4e, and R4g is optionally substituted with 1-2 substituents; with th e exclusion of a specified compound], and pharmaceutical acceptable salts thereof. Pharmaceutical compositions comprising compounds I, and methods of administering compounds I for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries. Thus, II was prepared from 2,4-dichlorothieno[2,3-d]pyrimidine and Et 2-(methylamino)acetate hydrochloride using 4-methoxy-2-(tributylstannyl)pyridine and 5-amino-2-methoxypyridine.. II was tested in an in vitro ferroportin internalization assay (pEC50 = 6.6). The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Safety of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

The Article related to thienopyrimidine preparation ferroportin inhibitor, preparation thienopyrimidine amino acid amide ferroportin inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 7, 1999, Pamukcu, Rifat; Piazza, Gary published a patent.Product Details of 42518-42-3 The title of the patent was Inhibition of neoplastic cells by exposure to thienopyrimidines. And the patent contained the following:

A method for inhibiting growth of neoplastic cells comprises administration of title compounds [I; R1, R2 = H, A, OA, alkenyl, alkynyl, NO2, CF3, halo; R3, R4 = H, A, OA, halo, NO2, amino; R3R4 = OCH2CH2, OCH2O, OCH2CH2O; X = substituted 5-7 membered heterocyclyl, isocyclyl; A = H, alkyl; n = 0-3; with provisos]. Thus, 2,4-dichloro-6-methylthieno[2,3-d]pyrimidine, 3,4-methylenedioxybenzylamine, and Et3N were stirred in CH2Cl2 to give 2-chloro-6-methyl-4-(3,4-methylenedioxybenzylamino)thieno[2,3-d]pyrimidine. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Product Details of 42518-42-3

The Article related to thienopyrimidine preparation neoplasm inhibitor, precancerous lesion treatment thienopyrimidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Product Details of 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 23, 2013, Madge, David; Chan, Fiona; John, Derek Edward; Edwards, Simon D.; Blunt, Richard; Hartzoulakis, Basil; Brown, Lindsay published a patent.SDS of cas: 42518-42-3 The title of the patent was Thienopyrimidines, furopyrimidines, thienopyridines and furopyridines useful as potassium channel inhibitors and their preparation. And the patent contained the following:

The invention provides compounds of formula I which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula I and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof. Compounds of formula I wherein A is O and S; X, V and Z are independently N and CR4, wherein one of two of V, X and Z are N; R1 is (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl and (un)substituted heteroaryl; R2 is H, halo, CN, CF3, etc.; R3 is H, halo, CN, CF3, (un)substituted alkyl, etc.; each R4 is independently H, halo, CN, CF3, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by N-alkylation of 2-(1-methylpyrrolidin-2-yl)ethanamine with 4-[4-(bromomethyl)-1-piperidyl]-5-phenyl-thieno[2,3-d]pyrimidine. The invention compounds were evaluated for their potassium channel inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of less than 500 nM. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).SDS of cas: 42518-42-3

The Article related to thienopyrimidine furopyrimidine thienopyridine furopyridine preparation potassium channel inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 1981, Yamaguchi, Hitoshi; Ishikawa, Fumiyoshi published an article.Formula: C8H6Cl2N2S The title of the article was Synthesis and reactions of 2-chloro-3,4-dihydrothienopyrimidines and -quinazolines. And the article contained the following:

Reaction of 2,4-dichlorothienopyrimidines and -quinazolines with NaBH4 gave the corresponding 2-chloro-3,4-dihydro derivatives, e.g. I, II, and III (R = Me, R1 = H; R = R1 = Cl). Some nucleophilic substitutions of I afforded 2-substituted derivatives; reaction of III (R = Me, R1 = H; R = R1 = Cl) with BrCH2CO2Et yielded selectively the corresponding 3-substituted compounds, which were converted to imidazoquinazolinones IV. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Formula: C8H6Cl2N2S

The Article related to thienopyrimidine chloro dihydro reaction, quinazoline chloro dihydro reaction, imidazoquinazolinone, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C8H6Cl2N2S

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia